NITD008

NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus.[1][2][3] However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.[4]

NITD008
Clinical data
Trade namesNITD008
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC13H14N4O4
Molar mass290.279 g·mol−1
3D model (JSmol)

See also
  • MK-608, a drug with a similar structure
  • Remdesivir, a drug with a similar structure currently undergoing clinical trials

References
  1. Yin, Z.; Chen, Y.-L.; Schul, W.; Wang, Q.-Y.; Gu, F.; Duraiswamy, J.; Kondreddi, R. R.; Niyomrattanakit, P.; Lakshminarayana, S. B.; Goh, A.; Xu, H. Y.; Liu, W.; Liu, B.; Lim, J. Y. H.; Ng, C. Y.; Qing, M.; Lim, C. C.; Yip, A.; Wang, G.; Chan, W. L.; Tan, H. P.; Lin, K.; Zhang, B.; Zou, G.; Bernard, K. A.; Garrett, C.; Beltz, K.; Dong, M.; Weaver, M.; et al. (2009). "An adenosine nucleoside inhibitor of dengue virus". Proceedings of the National Academy of Sciences. 106 (48): 20435–20439. Bibcode:2009PNAS..10620435Y. doi:10.1073/pnas.0907010106.
  2. Lo, Michael K.; Shi, Pei-Yong; Chen, Yen-Liang; Flint, Mike; Spiropoulou, Christina F. (2016). "In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses". Antiviral Research. 130: 46–49. doi:10.1016/j.antiviral.2016.03.013. PMC 5096641. PMID 27016316.
  3. Deng, Yong-Qiang; Zhang, Na-Na; Li, Chun-Feng; Tian, Min; Hao, Jia-Nan; Xie, Xu-Ping; Shi, Pei-Yong; Qin, Cheng-Feng (2016). "Adenosine Analog NITD008 is a Potent Inhibitor of Zika Virus". Open Forum Infectious Diseases. 3 (4): ofw175. doi:10.1093/ofid/ofw175.
  4. Nelson, Jacob; Roe, Kelsey; Orillo, Beverly; Shi, Pei-Yong; Verma, Saguna (2015). "Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection". Antiviral Research. 122: 39–45. doi:10.1016/j.antiviral.2015.07.008. PMC 4853296. PMID 26225754.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.